touchCONGRESS

Exploring the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Haematological Malignancies Watch Time: 64 mins

touchCONGRESS Exploring the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML

Watch this two-part activity exploring recent developments around the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA2021 Virtual Congress.

Part 1: Watch haematological cancer expert Prof. Uwe Platzbecker review key data from the EHA2021 Virtual Congress Watch Now
Part 2: Choose from leading experts who discuss what these data mean for global and regional practice Select An Interview

 

  • Part 1: Data Review
Next Chapter
Introduction
Mechanism of action and key clinical data for emerging treatments for higher-risk MDS
Current treatments and novel approaches for newly diagnosed AML, including management options when intensive induction therapy is not suitable
Current and future potential of immunotherapy and the use of MRD monitoring in MDS and AML
Video Player Controls:
 
Leave Feedback
Overview

Watch Prof. Uwe Platzbecker summarize and share his interpretation of the latest data from EHA2021 Virtual on emerging treatments for higher-risk MDS and newly diagnosed AML. During the presentation he considers:

  • Mechanism of action and key clinical data for emerging treatments for higher-risk MDS
  • Current treatments and novel approaches for newly diagnosed AML, including management options when intensive induction therapy is not suitable
  • Current and future potential of immunotherapy and the use of MRD monitoring in MDS and AML
About Prof. Uwe Platzbecker

After graduating from medical school in 1996, Prof. Platzbecker first started medical training in heart surgery. Since 1998, he worked at the Department of Hematology and Oncology at the University Hospital “Carl Gustav Carus” in Dresden, Germany. Between 2001 and 2003 he completed a 2-year postdoctoral fellowship provided by the Humboldt Foundation at the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. From 2012 to 2018 Prof. Platzbecker held the position of Professor of Hematology at the University Hospital “Carl Gustav Carus” in Dresden and was the head of the section of Hematology as well as chair of the medical ethics committee of the Technische Universität Dresden. In 2015 he was appointed as TransCampus Professor of Haematology at the Faculty of Life Sciences & Medicine at King’s College London, London UK. read more

Since October 2018, Prof. Platzbecker has been heading the hematology program at the University Hospital of Leipzig in Germany, as Director of the Medical Clinic of Hematology and Cell Therapy.

Prof. Platzbecker’s clinical expertise lies in haematological malignancies with a focus on MDS and AML. The main scientific interest involves the translational exploration of innovative treatment options for these patients involving the use of allogeneic haematopoietic stem cell transplantation. He is a member of the steering committee of the Study Alliance Leukemia and German MDS group. In 2012, Prof. Platzbecker co-founded the European Myelodysplastic Syndromes Cooperative Group (EMSCO).

Prof. Uwe Platzbecker discloses: Advisory board fees from AbbVie, BMS/Celgene, Geron, Janssen, Novartis and Takeda.

 

Downloads

View and download resources from this activity to support your learning or share with colleagues

  • Part 2: Expert Interviews
Leave Feedback
Prof. Uwe Platzbecker
Watch Time: 08:46
Medical Clinic of Hematology, University Hospital Leipzig, Leipzig, Germany

Uwe Platzbecker considers the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML from the EHA2021 Virtual Congress.

 
 
Leave Feedback
Interview Questions

In this interview, Uwe Platzbecker answers the following questions:

  • Based on data presented at EHA2021 Virtual, what do you consider to be the most promising novel treatments for patients with higher-risk MDS?
  • Are there any specific mutations targeted by any of the emerging treatments for higher-risk MDS? If so, is this likely to change current routine patient genetic analysis?
  • How is the treatment landscape evolving for patients with newly diagnosed AML? Are targeted therapies likely to replace intensive chemotherapy regimens for AML in the near future?
  • What criteria and/or assessment tools do you use for determining patient fitness for intensive therapy?
  • How do you see minimum residual disease (MRD) monitoring evolving in terms of methodology and standardization, and what impact do you see it having on the management of MDS and AML in the future?
About Prof. Uwe Platzbecker

After graduating from medical school in 1996, Prof. Platzbecker first started medical training in heart surgery. Since 1998, he worked at the Department of Hematology and Oncology at the University Hospital “Carl Gustav Carus” in Dresden, Germany. Between 2001 and 2003 he completed a 2-year postdoctoral fellowship provided by the Humboldt Foundation at the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. From 2012 to 2018 Prof. Platzbecker held the position of Professor of Hematology at the University Hospital “Carl Gustav Carus” in Dresden and was the head of the section of Hematology as well as chair of the medical ethics committee of the Technische Universität Dresden. In 2015 he was appointed as TransCampus Professor of Haematology at the Faculty of Life Sciences & Medicine at King’s College London, London UK. read more

Since October 2018, Prof. Platzbecker has been heading the hematology program at the University Hospital of Leipzig in Germany, as Director of the Medical Clinic of Hematology and Cell Therapy.

Prof. Platzbecker’s clinical expertise lies in haematological malignancies with a focus on MDS and AML. The main scientific interest involves the translational exploration of innovative treatment options for these patients involving the use of allogeneic haematopoietic stem cell transplantation. He is a member of the steering committee of the Study Alliance Leukemia and German MDS group. In 2012, Prof. Platzbecker co-founded the European Myelodysplastic Syndromes Cooperative Group (EMSCO).

Prof. Uwe Platzbecker discloses: Advisory board fees from AbbVie, BMS/Celgene, Geron, Janssen, Novartis and Takeda.

Prof. Valeria Santini
Watch Time: 19:13
Careggi University Hospital, University of Florence, Florence, Italy

Valeria Santini considers the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML from the EHA2021 Virtual Congress.

 
 
Leave Feedback
Interview Questions

In this interview, Valeria Santini answers the following questions:

  • Based on data presented at EHA2021 Virtual, what do you consider to be the most promising novel treatments for patients with higher-risk MDS?
  • Are there any specific mutations targeted by any of the emerging treatments for higher-risk MDS? If so, is this likely to change current routine patient genetic analysis?
  • How is the treatment landscape evolving for patients with newly diagnosed AML? Are targeted therapies likely to replace intensive chemotherapy regimens for AML in the near future?
  • What criteria and/or assessment tools do you use for determining patient fitness for intensive therapy?
  • How do you see minimum residual disease (MRD) monitoring evolving in terms of methodology and standardization, and what impact do you see it having on the management of MDS and AML in the future?
About Prof. Valeria Santini

Valeria Santini is Associate Professor of Hematology at the University of Florence, Italy. She received her medical degree from the University of Florence and became a Consultant in Hematology. She worked as a fellow of the European Organisation for Research and Treatment of Cancer (EORTC) at Dr Daniel den Hoed Cancer Center/Erasmus University, Rotterdam, The Netherlands. She then undertook clinical training in the USA at the Leukemia Unit, MD Anderson Cancer Center, University of Texas, Houston, TX. read more

Prof. Santini runs the MDS Unit in the Hematology Department, Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Florence, Italy. Her interests are focused on clinical and translational research in MDS and elderly AML.

Prof. Santini is President of the Fondazione Italiana per lo Studio delle Sindromi mielodisplastiche (FISM) and Italian Network of MDS Registries, a member of the Medical Advisory Board of the Aplastic Anemia and Myelodysplastic syndromes International Foundation (AAMDSIF) and a member of the board of GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) MDS working party. She is one of the three key opinion leaders for the MDS working group in the European Harmony 2020 research project. She is a member of the Scientific Committee of the European School of Hematology (ESH), the Education Committee of the Society of Hematologic Oncology (SOHO) and the Executive Board of the Scientific Working Group on MDS of the European Hematology Association (EHA). She has served for two terms on the executive board of the Italian Society of Hematology (SIE) and she has been Vice-president of the Italian Society of Experimental Hematology (SIES). She belongs to the American Society of Hematology (ASH), EHA and the MDS Foundation. She is also an author of more than 200 peer-reviewed papers published in international journals. She is on the Editorial Board of the journal Blood, and a documented reviewer for high impact factor scientific journals. She has been an invited speaker at numerous international annual meetings including those of the American Society of Clinical Oncology (ASCO), ASH and EHA, as well as the national haematology societies of several countries.

Prof. Valeria Santini discloses: Consultancy fees from BMS, Geron, Gilead, Menarini, Novartis and Takeda; and Funding from BMS/Celgene.

Prof. Andrew Wei
Watch Time: 13:09
Alfred Hospital and Monash University, Melbourne, Australia

Andrew Wei considers the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML from the EHA2021 Virtual Congress.

 
Leave Feedback
Interview Questions

In this interview, Andrew Wei answers the following questions:

  • Based on data presented at EHA2021 Virtual, what do you consider to be the most promising novel treatments for patients with higher-risk MDS?
  • Are there any specific mutations targeted by any of the emerging treatments for higher-risk MDS? If so, is this likely to change current routine patient genetic analysis?
  • How is the treatment landscape evolving for patients with newly diagnosed AML? Are targeted therapies likely to replace intensive chemotherapy regimens for AML in the near future?
  • What criteria and/or assessment tools do you use for determining patient fitness for intensive therapy?
  • How do you see minimum residual disease (MRD) monitoring evolving in terms of methodology and standardization, and what impact do you see it having on the management of MDS and AML in the future?
About Prof. Andrew Wei

Adjunct Professor Andrew Wei is a haematologist and Medical Research Future Fund Fellow at Alfred Hospital in Melbourne, Australia, where he conducts clinical and translational AML research in collaboration with Monash University, Melbourne. He joined Alfred Hospital in 2008 where he has led the AML program as principal investigator. He has authored >100 publications in peer-reviewed journals and has been the AML working party chairperson for the Australasian Leukaemia and Lymphoma Group (ALLG) since 2009.

Prof. Andrew Wei discloses: Consultancy for Servier; Honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer and Servier; Participation on advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer and Servier; Research grants from Abbvie, Amgen, AstraZeneca, Celgene/BMS, Novartis, Servier and F Hoffmann-La Roche; and Royalties in relation to venetoclax, for which, as a former employee of the Walter and Eliza Hall Institute, he is eligible for a fraction of the royalty stream.

Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Stay up to date with the  latest data on new and emerging treatments for the improvement of outcomes in higher-risk myelodysplastic syndromes (MDS) and newly diagnosed acute myeloid leukaemia (AML) in this two-part activity. This activity was filmed following the EHA2021 Virtual Congress.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the mechanisms of action and key clinical data for emerging treatments for higher-risk MDS
  • Evaluate current treatments and novel approaches for newly diagnosed AML, including management options when intensive induction therapy is not suitable
  • Discuss the current and future potential of immunotherapy and the use of measurable residual disease (MRD) monitoring in MDS and AML
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72